Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Sharkey

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodiesPierre-Yves Brard, Habibe Karacay, Rhona Stein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 16, 2009
A novel method of 18F radiolabeling for PETWilliam J McBride, Robert M Sharkey, Habibe Karacay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Optimizing bispecific antibody pretargeting for use in radioimmunotherapyRobert M Sharkey, Habibe Karacay, Heidi Richel, et al.
Clinical Genitourinary Cancer|November 7, 2015
Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial CarcinomaBishoy Faltas, David M Goldenberg, Allyson J Ocean, et al.
Nature Medicine|November 1, 2005
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibodyRobert M Sharkey, Thomas M Cardillo, Edmund A Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograftHabibe Karacay, Pierre-Yves Brard, Robert M Sharkey, et al.
Frontiers in Pharmacology|April 16, 2015
A pretargeting system for tumor PET imaging and radioimmunotherapyFrançoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, et al.
Cancer|February 4, 2010
Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibodyFrits Aarts, Otto C Boerman, Robert M Sharkey, et al.
Molecular Imaging and Biology|July 26, 2014
Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenograftsCatharina M van Rij, Cathelijne Frielink, David M Goldenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2006
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor GroupJean-François Chatal, Loïc Campion, Françoise Kraeber-Bodéré, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodiesPierre-Yves Brard, Habibe Karacay, Rhona Stein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 16, 2009
A novel method of 18F radiolabeling for PETWilliam J McBride, Robert M Sharkey, Habibe Karacay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Optimizing bispecific antibody pretargeting for use in radioimmunotherapyRobert M Sharkey, Habibe Karacay, Heidi Richel, et al.
Clinical Genitourinary Cancer|November 7, 2015
Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial CarcinomaBishoy Faltas, David M Goldenberg, Allyson J Ocean, et al.
Nature Medicine|November 1, 2005
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibodyRobert M Sharkey, Thomas M Cardillo, Edmund A Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograftHabibe Karacay, Pierre-Yves Brard, Robert M Sharkey, et al.
Frontiers in Pharmacology|April 16, 2015
A pretargeting system for tumor PET imaging and radioimmunotherapyFrançoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, et al.
Cancer|February 4, 2010
Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibodyFrits Aarts, Otto C Boerman, Robert M Sharkey, et al.
Molecular Imaging and Biology|July 26, 2014
Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenograftsCatharina M van Rij, Cathelijne Frielink, David M Goldenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2006
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor GroupJean-François Chatal, Loïc Campion, Françoise Kraeber-Bodéré, et al.
Pageof 12